This compound class has been reported to be active in a number of diseases dependent on either MYC or MYCN, including neuroblastoma, medulloblastoma, multiple myeloma, and non-Hodgkin Lymphoma (NHL), to name a few (50–54). The gene discussed is MYC; the disease is non-Hodgkin lymphoma.